01—Abstract
Summary
Summary of the 8-K filed May 6, 2026. Cited figures are marked; the original filing is the authoritative source.
AMETEK (NYSE: AME) announced on May 6, 2026 a definitive agreement to acquire a portfolio of instrumentation businesses from Indicor, LLC ("Indicor Instrumentation") in an all-cash transaction valued at approximately $5.0 billiona.
The businesses generate roughly $1.1 billionb in annual sales, carry profitability consistent with AMETEK, and will be integrated into the Electronic Instruments Group (EIG) and Electromechanical Group (EMG). Management cites a valuation of about 14x EBITDA and expects the deal to be cash earnings accretive in Year 1, with a strong return on capital. The deal is large relative to AMETEK's scale.
With annual sales of about $7.5 billionc, the target equals roughly 15% of AMETEK's revenue, and the $5.0 billion price is a major capital commitment. Funding will come from borrowings under the existing credit facility plus new debt issuance, with expected leverage at closing of about 2.3x. That leaves less balance sheet headroom for other capital deployment in the near term, though 2.3x is a manageable level for an investment-grade industrial.
Investors should watch the pace of deleveraging and the debt pricing that follows. Management highlights roughly 50%d aftermarket and recurring revenue, end-market overlap with existing AMETEK businesses, and synergies of 10% to 12% of sales. Those synergy figures are a central part of the value case and warrant scrutiny, since achieving them depends on integration execution.
The transaction is subject to customary conditions and regulatory approvals and is expected to close in the second half of 2026. The filing does not disclose the target's EBITDA margin or its standalone growth rate, so those inputs to the valuation cannot be independently verified from this document.
02—Key points
Key Highlights
- Definitive agreement to acquire Indicor Instrumentation from Indicor, LLC in an all-cash deal valued at approximately $5.0 billion
- Target generates about $1.1 billion in annual sales, roughly 15% of AMETEK's ~$7.5 billion revenue base, with profitability said to be consistent with AMETEK
- Valuation of approximately 14x EBITDA; management expects Year 1 cash earnings accretion and strong returns on capital
- Funding via existing credit facility borrowings and new debt issuance, with expected leverage at closing of about 2.3x
- Approximately 50% aftermarket/recurring revenue mix, supporting earnings resilience across the cycle
- Management targets annualized synergies of 10% to 12% of sales, roughly $110 million to $130 million on the target's sales base
- Expected to close in the second half of 2026, subject to customary conditions and regulatory approvals
03—Questions
Frequently Asked Questions
How large is this acquisition relative to AMETEK?
The target generates about $1.1 billion in annual sales against AMETEK's roughly $7.5 billion, so it adds about 15% to revenue. At $5.0 billion, the price is a substantial commitment and would be AMETEK's largest acquisition on the basis of the disclosed figures, though the filing does not explicitly rank it against past deals.
How will AMETEK pay for the deal, and what will leverage look like?
AMETEK plans to fund the purchase with borrowings under its existing credit facility and new debt issuance. Management expects leverage at closing of about 2.3x, which is a moderate level for an industrial company of this profile. Investors should monitor the pace of debt reduction after closing and any impact on share repurchases or dividends.
Where will the acquired businesses fit within AMETEK?
The businesses will be integrated into AMETEK's Electronic Instruments Group (EIG) and Electromechanical Group (EMG) based on product offerings and market alignment. The investor presentation lists the target's businesses as serving medical, aerospace and defense, power, research, and food and beverage end markets, with combined end-market mixes that are closely aligned with AMETEK's existing portfolio.
What are the main risks and what could prevent closing?
The deal is subject to customary closing conditions and regulatory approvals, which are not detailed in the filing. Key risks include integration execution, realizing the targeted 10% to 12% synergies, and the cost of new debt. The filing gives no detail on the regulatory review timeline or any break fees.
When is the transaction expected to close and how will it affect earnings?
The transaction is expected to close in the second half of 2026. Management expects it to be cash earnings accretive in Year 1, though the filing does not quantify the accretion or provide guidance on GAAP earnings, which will be affected by acquisition costs, amortization, and interest expense.
04—Continue